Please wait while the formulary information is being retrieved.
Drug overview for BENZEDREX (propylhexedrine):
Generic name: PROPYLHEXEDRINE
Drug class: Nasal Decongestants
Therapeutic class: Respiratory Therapy Agents
Propylhexedrine, an aliphatic amine that is structurally related to amphetamine, is a vasoconstrictor.
No enhanced Uses information available for this drug.
Generic name: PROPYLHEXEDRINE
Drug class: Nasal Decongestants
Therapeutic class: Respiratory Therapy Agents
Propylhexedrine, an aliphatic amine that is structurally related to amphetamine, is a vasoconstrictor.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for BENZEDREX (propylhexedrine) have been approved by the FDA:
Indications:
Nasal congestion
Professional Synonyms:
Nasal stuffiness
Indications:
Nasal congestion
Professional Synonyms:
Nasal stuffiness
The following dosing information is available for BENZEDREX (propylhexedrine):
In adults and in children 6 years of age and older, the usual dosage is 2 inhalations (approximately 0.4-0.5 mg of the drug) through each nostril at intervals of not less than 2 hours. In children less than 6 years of age, dosage must be determined by a physician. Propylhexedrine therapy should not exceed 3-5 days in duration.
Propylhexedrine is administered by nasal inhalation via an inhaler. Containers of the drug should be warmed in the hands before use to increase volatility of the drug. Care should be taken to avoid contamination of the inhaler and inhalants should not be used by more than one patient. Inhalants should be inhaled through each nostril with the patient's head erect, and 3-5 minutes later the nose should be blown thoroughly.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for BENZEDREX (propylhexedrine):
There are 0 contraindications.
There are 2 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Ergot Alkaloids/Sympathomimetics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Concurrent use of ergot alkaloids and sympathomimetics may result in additive or synergistic effect on peripheral blood vessels. CLINICAL EFFECTS: Concurrent use of ergot alkaloids and sympathomimetics may result in increased blood pressure due to peripheral vasoconstriction. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: When possible, avoid the concurrent use of ergot alkaloids and sympathomimetics. If concurrent use is warranted, monitor blood pressure and for signs of vasoconstriction. Decreasing the dose of one or both drugs may be necessary. DISCUSSION: There have been reports of severe vasoconstriction resulting in gangrene in patients receiving intravenous ergonovine with dopamine or norepinephrine. |
DIHYDROERGOTAMINE MESYLATE, ERGOLOID MESYLATES, ERGOMAR, ERGOTAMINE TARTRATE, ERGOTAMINE-CAFFEINE, METHYLERGONOVINE MALEATE, METHYSERGIDE MALEATE, MIGERGOT, MIGRANAL, TRUDHESA |
| Iobenguane I 123/Agents that Affect Catecholamines SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Many compounds that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells.(1) CLINICAL EFFECTS: Compounds that reduce catecholamine uptake or that deplete catecholamine stores may interfere with imaging completed with iobenguane.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Discuss the use of agents that affect catecholamines. Discontinue drugs that reduce catecholamine uptake or deplete catecholamine stores prior to imaging with iobenguane. Before imaging with iobenguane, discontinue agents that affect catecholamines for at least 5 biological half-lives, as clinically tolerated.(1) DISCUSSION: Many agents may reduce catecholamine uptake or deplete catecholamine stores.(1) Examples include: - CNS stimulants or amphetamines (e.g. cocaine, methylphenidate, dextroamphetamine) - norepinephrine and dopamine reuptake inhibitors (e.g. phentermine) - norepinephrine and serotonin reuptake inhibitors (e.g. tramadol) - monoamine oxidase inhibitors (e.g. phenelzine, linezolid) - central monoamine depleting drugs (e.g. reserpine) - non-select beta adrenergic blocking drugs (e.g. labetalol) - alpha agonists or alpha/beta agonists (e.g. pseudoephedrine, phenylephrine, ephedrine, phenylpropanolamine, naphazoline) - tricyclic antidepressants or norepinephrine reuptake inhibitors (e.g. amitriptyline, bupropion, duloxetine, mirtazapine, venlafaxine) - botanicals that may inhibit reuptake of norepinephrine, serotonin or dopamine (e.g. ephedra, ma huang, St. John's Wort, yohimbine) |
ADREVIEW |
There are 1 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Zavegepant/Intranasal Decongestants SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Intranasal decongestants may decrease the absorption of zavegepant.(1) CLINICAL EFFECTS: Concurrent administration of intranasal decongestants may result in decreased systemic exposure and effectiveness of zavegepant.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Avoid concurrent use of intranasal decongestants with zavegepant. If concurrent use is unavoidable, use the decongestant at least 1 hour after zavegepant.(1) DISCUSSION: Intranasal decongestants may lower absorption of zavegepant. This effect has not been clinically evaluated.(1) |
ZAVZPRET |
The following contraindication information is available for BENZEDREX (propylhexedrine):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 0 severe contraindications.
There are 0 moderate contraindications.
The following adverse reaction information is available for BENZEDREX (propylhexedrine):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 3 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Cardiac arrhythmia Chest pain Hallucinations |
There are 10 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Nasal passage irritation Rebound nasal congestion Rhinorrhea Sneezing |
| Rare/Very Rare |
|---|
|
Acute cognitive impairment Agitation Chest tightness Paranoid disorder Symptoms of anxiety Tachycardia |
The following precautions are available for BENZEDREX (propylhexedrine):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Safe use of propylhexedrine during pregnancy has not been established.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for BENZEDREX (propylhexedrine):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for BENZEDREX (propylhexedrine)'s list of indications:
| Nasal congestion | |
| R09.81 | Nasal congestion |
Formulary Reference Tool